You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
阿斯利康(AZN.US)溢價97%收購腫瘤藥企Fusion(FUSN.US) 涉資達24億美元
英國藥業巨擘阿斯利康(AZN.US)提出以20億美元現金收購臨床階段生物製藥公司Fusion Pharmaceuticals(FUSN.US),以擴大其腫瘤產品組合。阿斯利康將以每股21美元的價格收購Fusion,較這家美國上市公司周一(18日)收盤價溢價逾97%。在達到特定監管里程碑時,阿斯利康還將支付每股3美元的不可轉讓或有價值權,使合併交易價值達到約24億美元。 Fusion是一家腫瘤醫藥研發公司,專注於開發下一代放射性藥物以實現精準醫學,目前主打靶向α療法(TATs)管道。Fusion隔晚收報10.64美元,該股過去12個月累升165%,有分析師曾預測該股有潛質被收購。 阿斯利康英股(AZN.L)周二早段跌1.1%,報10,176便士。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account